Theravance Announces Initiation of Proof of Concept Phase 2 Clinical Study with its PUMA Compound, TD-1211, for the Treatment of Opioid-Induced Constipation
Theravance Announces Initiation of Proof of Concept Phase 2 Clinical Study with its PUMA Compound, TD-1211, for the Treatment of Opioid-Induced Constipation
Apr 14, 2010